Bharat Book Bureau Provides the Trending Market Research Report on “Global Specimen Validity Testing Market, Forecast to 2023” under Life Sciences category. The report offers a collection of superior market research, market analysis, competitive intelligence and industry reports.
Global specimen validity testing market is projected to grow at 6.3% during the forecast period
The specimen validity testing market is expected to reach USD 1.49 billion by 2023 from USD 1.10 billion in 2018, at a CAGR of 6.3%. Growth in the drug screening market and the increase in workplace drug testing are fueling the growth of the specimen validity testing market. On the other hand, market growth may be limited to a certain extent due to the emergence of alternative drug screening tests (such as oral fluid drug screening test).
Request a free sample copy of Specimen Validity Testing Market Report @ https://www.bharatbook.com/MarketReports/Sample/Reports/1094094
Specimen validity testing services are expected to grow at the highest CAGR during the forecast period
The specimen validity testing market is segmented into products and services. The services segment is projected to register the highest CAGR during the forecast period; growth in this segment is attributed to the growing implementation of workplace drug testing in several countries, increasing number of drug screening tests, and the growing number of drug screening laboratories across the globe.
By type, laboratory testing is expected to dominate the market during the forecast period
The specimen validity testing market is segmented into laboratory testing and rapid/POC testing. The laboratory testing segment is expected to dominate the market during the forecast period. The accuracy of test results and cost-effectiveness of laboratory testing are other key factors driving the demand for this segment.
Asia Pacific to witness high growth during the forecast period
In 2018, North America is expected to account for the largest share of the market followed by Europe. However, Asia Pacific is expected to register the highest CAGR during the forecast period. The high growth in the APAC regional segment is attributed to the developing healthcare infrastructure, rising adoption of stringent regulatory guidelines for drug testing, increase in the number of illicit drug users, and strategic expansion of key market players in the region.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type: Tier 1 – 24%; Tier 2 - 32%; Tier 3 - 44%.
- By Designation: C-level- 26%; D-level- 30%; others--44%.
- By Region: North America-48%; Europe-37%; Asia Pacific-10%; RoW-5%.
List of companies profiled in the report
- Alere (Subsidiary of Abbott Laboratories) (US)
- Thermo Fisher (US)
- Scitek (US)
- LabCorp (US)
- Quest Diagnostics (US)
- Alfa Scientific Designs (US)
- American Bio Medica Corporation (US)
- Express Diagnostics (US)
- ACM Global Laboratories (US)
- Clinical Reference Laboratory (CRL)
- Premier Biotech (US)
Click the link below to read the Full report :
About Bharat Book Bureau:
Bharat Book Bureau is the leading market research information provider for market research reports, company profiles, industry study, country reports, business reports, newsletters and online databases. Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. We cover sectors starting from Aeronautics to Zoology.
Contact us at:
Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Follow us on : Twitter, Facebook, LinkedIn, Google Plus
Bharat Book Bureau, the leading market research information aggregator provides market research reports, company profiles, country reports, newsletters, and online databases for the past twenty four years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our market research reports help global companies to know different market before starting up business / expanding in different countries across the world.